Pharmacologic inhibition of Protein Kinase C α and Protein Kinase C β halts renal function decline indirectly, by blunting hyperphagia, and directly reduces adiposity in the ZSF1 rat model of type 2 diabetes
Wang, J.; Casimiro-Garcia, A.; Johnson, B. G.; Duffen, J.; Cain, M.; Savary, L.; Wang, S.; Nambiar, P.; Lech, M.; Zhao, S.; Xi, L.; Zhan, Y.; Olson, J.; Stejskal, J. A.; Lin, H.; Zhang, B.; Martinez, R.; Masek-Hammerman, K.; Schlerman, F. J.; Dower, K.
Show abstract
Type 2 diabetes (T2D) and its complications can have debilitating, sometimes fatal consequences. Despite advances that address some of the metabolic aspects of T2D, for many patients these approaches do not sufficiently control the disease. As a result, an emerging therapeutic strategy is to target the pathobiological mechanisms downstream of T2D metabolic derangement that can result in organ damage, morbidity, and mortality in afflicted individuals. One such proposed mechanism involves the Protein Kinase C (PKC) family members PKC and PKC{beta}, which have been linked to diabetes-induced tissue damage to organs including the kidneys. To evaluate the therapeutic potential of dual inhibition of PKC and PKC{beta} in the context of T2D, we have evaluated a potent and orally bioavailable inhibitor, herein referred to as Cmpd 1, in the ZSF1 rat model of leptin-receptor deficiency, obesity-driven T2D. Therapeutic dosing of Cmpd 1 virtually halted renal function decline but did so indirectly by blunting the hyperphagia response of these animals. Beyond this clear but indirect effect, Cmpd 1 had direct and prominent effects on body weight and in liver and inguinal white adipose tissue (iWAT) when administered to ZSF1 obese rats.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Loss of long-chain acyl-CoA dehydrogenase protects against acute kidney injury 94%
- NAD+ activates renal metabolism and protects from chronic kidney disease in a model of Alport syndrome 94%
- Beta-cell mass expansion during puberty involves serotonin signaling and determines glucose homeostasis in adulthood 93%
Similar papers in this journal
- Targeted and selective knockout of the TLQP-21 neuropeptide unmasks its unique role in energy homeostasis 95%
- Mechanisms underlying the efficacy of a rodent model of vertical sleeve gastrectomy - a focus on energy expenditure 95%
- Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues. 95%
Similar papers in this journal
- The non-steroidal mineralocorticoid receptor (MR) antagonist (FINERENONE) reverses Western diet-induced kidney disease by enhancing mitochondrial metabolism and decreasing lipid accumulation and inflammation 96%
- Farnesoid X receptor agonism prevents neutrophil extracellular traps via reduced sphingosine-1-phosphate in chronic kidney disease 95%
- Cystinosin deficient rats recapitulate the phenotype of nephropathic cystinosis 94%
Similar papers in this journal
- Daily transient coating of the intestine leads to weight loss and improved glucose tolerance 96%
- PPARalpha-ERRalpha crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression 92%
- Hypothalamic C2-domain protein involved in MC4R trafficking and control of energy balance 92%
Similar papers in this journal
- A Peptide Triple Agonist of GLP-1, Neuropeptide Y1, and Neuropeptide Y2 Receptors Promotes Glycemic Control and Weight Loss 95%
- Deficiency of the lipid flippase ATP10A causes diet-induced dyslipidemia in female mice 95%
- Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion. 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.